Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409406 | 0.88 | ALDH1A1 (0.54) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL29957009 | 0.83 | MAPT (0.50) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL8081123 | 0.81 | PTGER4 (0.64) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1429516 | 0.80 | PTGER4 (0.50) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL18271504 | 0.80 | KDM4E (0.56) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1429306 | 0.80 | KDM4E (0.50) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL7598707 | 0.80 | POLB (0.55) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL25225487 | 0.80 | KDM4E (0.50) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12721222 | 0.79 | FBP1 (0.48) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL7603198 | 0.79 | ALDH1A1 (0.65) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056913-A1 | COMPOUND AND METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-20 | — | — | WO | disclosed |
| CN-113563336-B | Evodiamine prodrug containing indoloquinone unit and preparation method and application thereof | 陕西中医药大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-113563336-A | Evodiamine prodrug containing indoloquinone unit and preparation method and application thereof | 陕西中医药大学 | 2021-10-29 | — | — | CN | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-20120322800-A1 | Sepiapterin Reductase Inhibitors For The Treatment of Pain | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120322800-A1 | Sepiapterin Reductase Inhibitors For The Treatment of Pain | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2011047156-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1264825-A1 | Beta-Hydroxyalkylpicoliniumsalts | Bayer Aktiengesellschaft (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-5840902-A | REACTING PICOLINE WITH ALKYLENE OXIDE IN PRESENCE OF ACID IN WATER OR MIXTURE OF WATER AND POLAR SOLVENT | BAYER AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| WO-1997023456-A1 | INDOLOQUINONE DERIVATIVES AS BIOREDUCTIVE AGENTS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1997-07-03 | — | — | WO | disclosed |
| EP-0776888-A2 | Process for the preparation of beta-Hydrosyalkylpicolinium salts and picolinium salts as intermediates for the prepation of cationic dyes | BAYER AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| US-4513142-A | Preparation of cationic methine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1985-04-23 | — | — | US | disclosed |
| EP-0074569-A2 | Cationic methine dyes, process for their preparation and their use, in dyeing textile materials and other substrates | BAYER AG (DE) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SPR, QDPR, SRR | MEN1 4856/4885KMT2A 3756/4885NPC1 2778/4885 |
| US-20120322800-A1 | Sepiapterin Reductase Inhibitors For The Treatment of Pain | SPR, QDPR, SRR | MEN1 4856/4885KMT2A 3756/4885NPC1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.